<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Urolithiasis</journal-id><journal-id journal-id-type="iso-abbrev">Urolithiasis</journal-id><journal-title-group><journal-title>Urolithiasis</journal-title></journal-title-group><issn pub-type="ppub">2194-7228</issn><issn pub-type="epub">2194-7236</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40392272</article-id><article-id pub-id-type="pmc">PMC12092508</article-id>
<article-id pub-id-type="publisher-id">1760</article-id><article-id pub-id-type="doi">10.1007/s00240-025-01760-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Safety and efficacy of Silodosin as medical expulsive therapy after shock wave lithotripsy in paediatric patients &#x0200d;&#x0200d;with renal stones</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Amer</surname><given-names>Mohammed Lotfi</given-names></name><address><email>drmlamer@med.tanta.edu.eg</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Elkholefy</surname><given-names>Mohamed Essam</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dawoud</surname><given-names>Heba</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gaber</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>El-gamal</surname><given-names>Osama Mostafa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gameel</surname><given-names>Tarek</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/005gf6j43</institution-id><institution-id institution-id-type="GRID">grid.479691.4</institution-id><institution>Urology Department, Faculty of Medicine, </institution><institution>Tanta University Hospital, </institution></institution-wrap>Tanta, Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/005gf6j43</institution-id><institution-id institution-id-type="GRID">grid.479691.4</institution-id><institution>Paediatric Department, Faculty of Medicine, </institution><institution>Tanta University Hospital, </institution></institution-wrap>Tanta, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>53</volume><issue>1</issue><elocation-id>95</elocation-id><history><date date-type="received"><day>11</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">This study was designed to assess the safety and efficacy of Silodosin as a medical expulsive therapy following shockwave lithotripsy (SWL) in paediatric patients with renal stones. In this prospective randomized controlled study conducted at Tanta University Hospital from January 2022 to March 2024, thirty children with a single de novo radiopaque renal pelvic stone less than 2&#x000a0;cm scheduled for SWL were randomized into two equal groups. Group A (<italic>n</italic>&#x02009;=&#x02009;15) received Silodosin 4&#x000a0;mg once daily after the first SWL session, and Group B (<italic>n</italic>&#x02009;=&#x02009;15) received a matching placebo. The first dose was administered on the night of the initial SWL session and continued until stone-free status was confirmed, for a maximum of 4 weeks. The stone expulsion time was set as a primary outcome, while the secondary outcomes were one-session stone-free rate (SFR), postoperative pain scores, and Silodosin related adverse events. The results showed that the mean stone expulsion time in group A (11.4&#x02009;&#x000b1;&#x02009;1.8 days) was significantly shorter compared to group B (16.4&#x02009;&#x000b1;&#x02009;1.6 days; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). One-session SFR was 86.6% in Silodosin group compared to 73.3% in Placebo group (<italic>P</italic>&#x02009;=&#x02009;0.6). Pain visual analogue scores were significantly lower in group A (2.31&#x02009;&#x000b1;&#x02009;1.75) than in group B (5.08&#x02009;&#x000b1;&#x02009;2.43; <italic>P</italic>&#x02009;=&#x02009;0.003). No severe drug-related adverse effects were reported in either group. In conclusion, Silodosin appears to be a safe and effective adjunct to SWL in paediatric patients, significantly reducing stone expulsion time and postoperative pain. Larger studies are needed to confirm these findings.</p></abstract><trans-abstract xml:lang="de" id="Abs2"><title>Trial registration number</title><p id="Par2">PACTR202503893791588 (retrospectively registered).</p></trans-abstract><kwd-group xml:lang="de"><title>Keywords</title><kwd>Paediatric renal stones</kwd><kwd>Shockwave lithotripsy</kwd><kwd>Medical expulsive therapy</kwd><kwd>Stone-Free rate</kwd></kwd-group><funding-group><award-group><funding-source><institution>Tanta University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Renal stones are becoming increasingly common in children, likely due to factors such as dietary habits, lifestyle changes, and environmental conditions [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. They can lead to significant health issues, including recurrent UTIs, pain, haematuria, and potential renal function deterioration, with urging need for effective management strategies [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par4">Shock wave lithotripsy (SWL) remains a standard non-surgical approach for managing renal calculi less than 2&#x000a0;cm in size, relying on shock waves to fragment stones into passable pieces [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, residual stone fragments can remain, necessitating additional interventions to prevent complications such as obstruction, infection, and recurrence [<xref ref-type="bibr" rid="CR25">25</xref>]. The first use of SWL in children was reported by Newman et al. in 1986 [<xref ref-type="bibr" rid="CR20">20</xref>]. Since this date, SWL has been reported as one of the pivotal options of treatment of pediatric stones with high success rate ranging from 70 to 96% and acceptable safety profile [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par5">Medical expulsive therapy (MET), often used alongside SWL, aims to facilitate the passage of stone fragments. Alpha 1 adrenoreceptors are highly distributed in the lower part of ureter and blockage of these receptors improves stone passage by inhibition of uncoordinated contractions and prevention of ureteric muscle spasm [<xref ref-type="bibr" rid="CR29">29</xref>]. Alpha-blockers, like Tamsulosin, have been shown to enhance stone clearance rates and shorten expulsion time by relaxing the ureteric smooth muscle [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. However, their use in paediatric patients remains unexplored, raising concerns regarding safety and efficacy [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par6">The safety of selective alpha antagonists in pediatrics especially Tamsulosin has been reported by various studies [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR32">32</xref>].In 2012, FDA approved the safety of Tamsulosin in children with daily dose of 0.2&#x000a0;mg for children under 5 years old and a conventional dose of 0.4&#x000a0;mg daily for older children [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par7">Silodosin, a selective &#x003b1;1A-adrenoceptor antagonist, targets the lower urinary tract&#x02019;s smooth muscle, potentially offering fewer systemic side effects than non-selective alpha-blockers, making it a promising option for paediatric patients [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. By blocking &#x003b1;1A adrenergic receptors -primarily found in the prostate and bladder neck- Silodosin facilitates muscle relaxation and stone passage [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. While effective in adults, its use in paediatric patients is not fully explored. This study aims to evaluate Silodosin&#x02019;s efficacy and safety as an adjunct therapy to SWL in children with renal pelvic stones.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and setting</title><p id="Par8">This study was a prospective, double-blind, randomized controlled trial conducted at the Department of Urology, Tanta University Hospital, from January 2022 to March 2024. Ethical approval (<italic>approval number 32649/10/18</italic>) was obtained, and informed consent was signed by the guardians of all participating children after thorough discussion about the benefits and the possible undesirable effects of the off-label use of Silodosin. The study was retrospectively registered in the Pan African Clinical Trials Registry <italic>(Trial registration number PACTR202503893791588).</italic></p></sec><sec id="Sec4"><title>Study population</title><p id="Par9">The study included paediatric patients under 18 years old with newly diagnosed single radiopaque renal pelvic stone scheduled for SWL.We excluded patients with a solitary kidney,congenital or acquired renal or ureteral abnormalities, significant hydronephrosis (as per Onen&#x02019;s criteria) [<xref ref-type="bibr" rid="CR21">21</xref>],presence of a JJ stent, active UTIs, or impaired renal function (eGFR&#x02009;&#x0003c;&#x02009;60 mL/min/1.73&#x000a0;m&#x000b2;).</p><p id="Par10">Thirty paediatric patients were enrolled, randomized and divided using computer randomization software [<xref ref-type="bibr" rid="CR26">26</xref>] into two equal groups (15 in each group) before the first SWL session <bold>(</bold>Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref><bold>).</bold></p><p id="Par11">
<list list-type="order"><list-item><p id="Par12">Silodosin group (Group A):Patients received 4&#x000a0;mg Silodosin (Sildocare 4&#x000a0;mg <sup>&#x000ae;</sup>, Andalous Pharma Company) as a single bedtime dose in a capsule form. The first dose was administered on the night of the initial SWL session and continued until stone-free status was confirmed, for a maximum of 4 weeks. For patients who had difficulty swallowing capsules, the contents were emptied and mixed with water, juice, or yogurt.</p></list-item><list-item><p id="Par13">Placebo Group (Group B):Patients received an identical placebo capsule as a single bedtime dose, ensuring the blinding of both participants and investigators.</p></list-item></list>
</p><p id="Par14">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of the study recruitment process</p></caption><graphic xlink:href="240_2025_1760_Fig1_HTML" id="d33e333"/></fig>
</p></sec><sec id="Sec5"><title>Sample size calculation</title><p id="Par15">The sample size calculation for this study was based on the primary endpoint, stone expulsion time for small ureteric stone fragments, comparing Silodosin to standard care following SWL for renal pelvic stones. Based on previous research, without MET after SWL, the passage of small stone fragments might long for 2&#x02013;4 weeks [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. We hypothesized that Silodosin use could reduce this time to 1&#x02013;2 weeks, based on similar studies on ureteric stones [<xref ref-type="bibr" rid="CR10">10</xref>], leading to a mean expulsion time of 14 days in the Silodosin group versus 21 days in the control group.</p><p id="Par16">Based on a two-sample t-test for continuous variables, with a two-sided alpha of 0.05 and 80% statistical power, the calculated minimum sample size needed for each group was 13 participants, resulting in a total of 26 patients. To account for potential dropouts and protocol deviations, we recruited 15 patients in each group with a total sample size of 30 patients.</p><p id="Par17">All participants underwent thorough preoperative evaluations, including a thorough medical evaluation, complete blood count, coagulation profile, renal function assessment, and urinalysis. Imaging studies (Kidney Ureter Bladder X-ray films (KUB), ultrasonography, non-contrast computed tomography scans of abdomen and pelvis NCCT) were conducted to confirm stone size and location. UTIs were treated with antibiotics prior to the procedure. Preoperative fasting was required (6&#x000a0;h for solids, 2&#x000a0;h for fluids).</p></sec><sec id="Sec6"><title>Anaesthesia and sedation</title><p id="Par18">Standardized anaesthesia protocols were used. General Anaesthesia (GA) was induced in all children less than 10 years or uncooperative children, using propofol (1&#x02013;2&#x000a0;mg/kg) and maintained with sevoflurane (2&#x02013;3%). Pain control measures included administration of paracetamol (15&#x000a0;mg/kg) or ibuprofen, with fentanyl (1&#x02013;2&#x000a0;&#x000b5;g/kg) as needed. Sedation was induced using Midazolam (0.1&#x02013;0.2&#x000a0;mg/kg) when GA was not required. Continuous monitoring of vital signs was implemented.</p></sec><sec id="Sec7"><title>Shock wave lithotripsy procedure</title><p id="Par19">SWL was performed using the Dornier Compact Delta II Lithotripter, under fluoroscopic guidance. The procedure involved 1,500 to 3,000 shocks per session, with power settings adjusted based on patient tolerance -if sedated- with a range of settings (14&#x02013;16&#x000a0;kV, 60&#x02013;80 shocks per minute).</p></sec><sec id="Sec8"><title>Patient instructions</title><p id="Par20">Patients and guardians were provided with standardized instructions to enhance compliance and data accuracy:</p><p id="Par21">
<list list-type="order"><list-item><p id="Par22">The patients received dietary guidance to promote hydration (at least 2&#x000a0;L of water daily) and engage in regular physical activity. Adherence was tracked through diaries.</p></list-item><list-item><p id="Par23">Pain Management Protocol:Diclofenac (1&#x02013;2&#x000a0;mg/kg) was administered orally or rectally guided by the severity of pain episodes. If pain was not responding to regular analgesia, in hospital admission was requested.</p></list-item><list-item><p id="Par24">Symptom Diary: Record episodes of pain, analgesic use, and stone expulsion events.</p></list-item><list-item><p id="Par25">Monitoring Stone Passage: Use a potty for voiding to monitor and collect expelled stone fragments for chemical analysis.</p></list-item><list-item><p id="Par26">Haematuria Monitoring:&#x0200d;&#x0200d; Observe urine for blood and report the duration until it clears.</p></list-item><list-item><p id="Par27">Emergency Protocol:&#x0200d;&#x0200d; Seek immediate medical attention for fever, persistent pain, or prolonged haematuria.</p></list-item></list>
</p></sec><sec id="Sec9"><title>Post-procedural monitoring and Follow-Up</title><p id="Par28">All patients were subjected to regular follow up visits twice weekly; however, they were monitored radiologically at two time points (2 and 4 weeks of starting the treatment) using KUB radiographs and ultrasonography to assess stone clearance. Stone free status was defined as no stones or &#x0003c;&#x02009;4&#x000a0;mm fragments in radiological studies after 2 or 4 weeks of SWL session. Presence of stone fragments (&#x0003e; 4&#x000a0;mm) after 4 weeks was an indication for another SWL session.</p><p id="Par29">Stone expulsion time was recorded as the number of days from the first SWL session until the last stone fragment was visually confirmed to have passed. This was confirmed by absence of ureteric stone fragments during radiological assessments at the checkpoints 2 and 4 weeks.</p><p id="Par30">Follow up assessments included measurement of blood pressure and pulse rate in pediatric reception. The cuff of the used sphygmomanometer should be appropriate to arm size as its width must be 40% of the arm circumference at mid arm point between acromion and olecranon. The recommended size of cuff in infant is 6&#x02009;&#x000d7;&#x02009;12&#x000a0;cm and the recommended size in older children is 9&#x02009;&#x000d7;&#x02009;18&#x000a0;cm. The child should be rested and relaxed with his right arm at the level of the heart.</p><p id="Par31">For both study groups, data collection included stone expulsion time and rate, number and intensity of pain episodes, analgesic consumption, and any adverse events. Serious complications were immediately reported to the principal investigator and the institutional ethics committee.</p><p id="Par32">Pain severity was assessed using the Visual Analogue Scale (VAS), with scores provided by the parents [<xref ref-type="bibr" rid="CR35">35</xref>]. Any instance of abdominal pain, whether typical of renal colic or atypical, that required administration of analgesics during the study duration was defined as a pain episode. Following stone expulsion, the patients were referred to paediatric department for dedicated metabolic evaluations and tailored management strategies.</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par33">Collected data included pain scores, analgesic usage, stone expulsion time, one session SFR, duration of haematuria, and adverse events. Baseline characteristics, stone expulsion time, pain scores, one session stone clearance rates, and adverse events were evaluated using suitable statistical assessments, such as descriptive statistics, independent t-tests, Chi-square tests, and Fisher&#x02019;s exact test where applicable. Data analysis was performed with SPSS version 27, considering a p-value&#x02009;&#x0003c;&#x02009;0.05 as statistically significant and presenting results with 95% confidence intervals. To minimize bias and enhance internal validity, this study employed blinding and allocation concealment.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Patients demographic data</title><p id="Par34">Thirty children diagnosed with de novo renal pelvic stones were included in the current study, with comparable baseline demographic data <bold>(</bold>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref><bold>)</bold>. The mean age was 8.6&#x02009;&#x000b1;&#x02009;3.2 years in group A, and 8.9&#x02009;&#x000b1;&#x02009;3.2 years for group B. A higher percentage of males were noticed in group B (80%) compared to group A (53.3%). Right-sided kidney stones were more common in both groups. Symptoms such as nonspecific abdominal pain, haematuria, loin pain, and dysuria were comparable in both groups <bold>(</bold>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref><bold>)</bold>.</p><p id="Par35">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients&#x02019; demographic data and stones&#x02019; characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Silodosin Group</th><th align="left">Placebo Group</th><th align="left">Statistical test</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">
<bold>Age (years) &#x000b1; SD</bold>
</td><td align="left">8.6&#x02009;&#x000b1;&#x02009;3.2</td><td align="left">8.9&#x02009;&#x000b1;&#x02009;3.2</td><td align="left">t&#x02009;=&#x02009;0.359</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.46</td></tr><tr><td align="left">
<bold>Male n (%)</bold>
</td><td align="left">8 (53.3)</td><td align="left">12 (80)</td><td align="left" rowspan="2">X&#x000b2;=2.4</td><td align="left" rowspan="2"><italic>P</italic>&#x02009;=&#x02009;0.121</td></tr><tr><td align="left">
<bold>Female n (%)</bold>
</td><td align="left">7(46.7)</td><td align="left">3(20)</td></tr><tr><td align="left"><bold>Stone size</bold> (cm)</td><td align="left">1.31&#x02009;&#x000b1;&#x02009;0.19</td><td align="left">1.21&#x02009;&#x000b1;&#x02009;0.2</td><td align="left">t&#x02009;=&#x02009;1.829</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.187</td></tr><tr><td align="left"><bold>Hounsfield Unit (HU)</bold> m&#x000b1; SD</td><td align="left">836.67&#x02009;&#x000b1;&#x02009;106.01</td><td align="left">821.33&#x02009;&#x000b1;&#x02009;111.03</td><td align="left">t&#x02009;=&#x02009;0.15</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.702</td></tr><tr><td align="left" rowspan="2"><p>
<bold>Stone side</bold>
</p><p>Right kidney n (%)</p><p>Left kidney n (%)</p></td><td align="left">11(73.3)</td><td align="left">8(53.3)</td><td align="left" rowspan="2">X&#x000b2;=0.833</td><td align="left" rowspan="2"><italic>P</italic>&#x02009;=&#x02009;0.361</td></tr><tr><td align="left">4(26.7)</td><td align="left">7(46.7)</td></tr><tr><td align="left">
<bold>Complaint at presentation</bold>
</td><td align="left" colspan="4"/></tr><tr><td align="left">Non-specific abdominal pain</td><td align="left">7(46.7)</td><td align="left">11(73.3)</td><td align="left">2.222</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.136</td></tr><tr><td align="left">Haematuria</td><td align="left">6(40)</td><td align="left">4(26.7)</td><td align="left">0.6</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.43</td></tr><tr><td align="left">Loin pain</td><td align="left">5(33.3)</td><td align="left">4(26.7)</td><td align="left">0.159</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.69</td></tr><tr><td align="left">Dysuria</td><td align="left">3(20)</td><td align="left">2(13.3)</td><td align="left">0.269</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.604</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec13"><title>procedural data and stone outcomes</title><p id="Par36">General anaesthesia was used in 43.3% of cases, while 56.6% received sedation. Both groups underwent similar numbers of shock waves during SWL, with no significant differences in procedural characteristics <bold>(</bold>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref><bold>)</bold>. One session SFR was slightly higher in group A (86.6%) compared to group B (73.3%), but without statistically significant difference (<italic>P</italic>&#x02009;=&#x02009;0.65). The Cram&#x000e9;r&#x02019;s V for this comparison was 0.083, indicating a small effect size and suggesting a weak association between treatment group and stone clearance.</p><p id="Par37">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Procedure technical details and outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Silodosin Group</th><th align="left">Placebo Group</th><th align="left">Statistical test</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left"><bold>General Anaesthesia</bold> n (%)</td><td align="left">8(53.3)</td><td align="left">5(33.3)</td><td align="left">X&#x000b2;=3.333</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.068</td></tr><tr><td align="left"><bold>Number of Shocks</bold> m&#x02009;&#x000b1;&#x02009;SD</td><td align="left">2066.67&#x02009;&#x000b1;&#x02009;231.97</td><td align="left">2126.67&#x02009;&#x000b1;&#x02009;357.50</td><td align="left">t&#x02009;=&#x02009;0.297</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.59</td></tr><tr><td align="left"><bold>Frequency of shock waves</bold> m&#x02009;&#x000b1;&#x02009;SD</td><td align="left">71.33&#x02009;&#x000b1;&#x02009;8.34</td><td align="left">77&#x02009;&#x000b1;&#x02009;7.75</td><td align="left">3.719</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.064</td></tr><tr><td align="left"><bold>Procedure Time (minutes)</bold>&#x02009;&#x000b1;&#x02009;SD</td><td align="left">30&#x02009;&#x000b1;&#x02009;3.78</td><td align="left">30.67&#x02009;&#x000b1;&#x02009;4.17</td><td align="left">t&#x02009;=&#x02009;0.211</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.65</td></tr><tr><td align="left"><bold>One session SFR</bold> n (%)</td><td align="left">13(86.7)</td><td align="left">11(73.3)</td><td align="left">X&#x000b2;=0.833</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.6</td></tr><tr><td align="left"><bold>Stone Expulsion Time (days)</bold> m&#x02009;&#x000b1;&#x02009;SD</td><td align="left">11.4&#x02009;&#x000b1;&#x02009;1.8</td><td align="left">16.4&#x02009;&#x000b1;&#x02009;1.6</td><td align="left">t&#x02009;=&#x02009;49.545</td><td align="left"><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">
<bold>Complications after SWL</bold>
</td><td align="left" colspan="4"/></tr><tr><td align="left">Mild visible haematuria n (%)</td><td align="left">6(40)</td><td align="left">5(33.3)</td><td align="left">X&#x000b2;=0.142</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.705</td></tr><tr><td align="left">Significant Pain n (%)</td><td align="left">6(40)</td><td align="left">13(86.7)</td><td align="left">X&#x000b2;=7.032</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.008</td></tr><tr><td align="left"><p>Hypotension</p><p>Fever</p><p>Subcapsular hematoma</p></td><td align="left">0</td><td align="left">0</td><td align="left">-</td><td align="left">
<italic>-</italic>
</td></tr><tr><td align="left">
<bold>Drug related adverse events</bold>
</td><td align="left" colspan="4"/></tr><tr><td align="left">Gastrointestinal Symptoms n (%)</td><td align="left">3(20)</td><td align="left">0</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Headache/Dizziness n (%)</td><td align="left">2(13.3)</td><td align="left">0</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left"><bold>Post procedure Pain Score</bold> m&#x02009;&#x000b1;&#x02009;SD</td><td align="left">2.31&#x02009;&#x000b1;&#x02009;1.75</td><td align="left">5.08&#x02009;&#x000b1;&#x02009;2.43</td><td align="left">t&#x02009;=&#x02009;11.109</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.003</td></tr><tr><td align="left"><bold>Analgesic Need</bold> n (%)</td><td align="left">6(40)</td><td align="left">13(86.7)</td><td align="left">X&#x000b2;=7.032</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.008</td></tr><tr><td align="left"><bold>Need for Analgesic Injection</bold> n (%)</td><td align="left">2(13.3)</td><td align="left">7(46.7)</td><td align="left">X&#x000b2;=3.968</td><td align="left"><italic>P</italic>&#x02009;=&#x02009;0.046</td></tr></tbody></table></table-wrap>
</p><p id="Par38">On the contrary, the mean stone expulsion time was significantly shorter in group A (11.4&#x02009;&#x000b1;&#x02009;1.8 days) compared to group B (16.4&#x02009;&#x000b1;&#x02009;1.6 days; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) <bold>(</bold>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref><bold>)</bold>. The Cohen&#x02019;s d for this difference was &#x02212;&#x02009;2.94, indicating a very large effect size. This suggests that Silodosin accelerates the stone expulsion process by almost 3 standard deviations, highlighting its substantial clinical benefit in reducing expulsion time. Therefore, while Silodosin improved stone expulsion time, it did not significantly influence the overall clearance of stones after one session of SWL compared to placebo.</p></sec><sec id="Sec14"><title>Complications and pain management</title><p id="Par39">Only minor complications (Clavien-Dindo grade 1) were reported in 56.6% of patients, primarily mild visible haematuria and postoperative pain. Haematuria occurred in 40% of the children in group A and 33.3% of the patients in group B, with no significant difference. Postoperative pain scores were significantly lower in the group A (2.31&#x02009;&#x000b1;&#x02009;1.75) compared to group B (5.08&#x02009;&#x000b1;&#x02009;2.43; <italic>p</italic>&#x02009;=&#x02009;0.003). The analgesics use was also significantly reduced in the group A (40% vs. 86.7% in group B; <italic>p</italic>&#x02009;=&#x02009;0.008) <bold>(</bold>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref><bold>)</bold>. The Cohen&#x02019;s d for this comparison was &#x02212;&#x02009;1.31, indicating a large effect size. This demonstrates that Silodosin effectively reduces postoperative pain, with a clinically meaningful difference of more than 1.3 standard deviations between the groups.</p><p id="Par40">Six children (20%); 2 in group A (6.6%) and 4 in group B (13.3%) who needed a second SWL session. All their fragments were inside the kidneys without any ureteric stones detected. Five of these patients were stone free after the 2nd SWL session and only one patient in group B needed a 3rd SWL session and became stone free after that. None of the patients required an auxiliary procedure other than SWL.</p></sec><sec id="Sec15"><title>drug related adverse events and metabolic findings</title><p id="Par41">Adverse events associated with Silodosin were mild, with gastrointestinal symptoms (nausea and vomiting) reported in 20% of patients, resolving without intervention. No episodes of hypotension were noted, however two patients experienced transient headache and dizziness episodes which didn&#x02019;t affect their compliance to medication <bold>(</bold>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref><bold>)</bold>.</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par42">In the present study, we examined the effectiveness of Silodosin as a MET following shock wave lithotripsy (SWL) for children with a de novo single renal pelvic stone smaller than 2&#x000a0;cm. All stones were radiopaque, with a mean size of 1.2&#x02009;&#x000b1;&#x02009;0.3&#x000a0;cm and a mean stone density of 829&#x02009;&#x000b1;&#x02009;106.9 HU. Radiolucent stones were excluded due to the lack of ultrasonic localization capabilities in our equipment.</p><p id="Par43">Regarding anaesthesia, GA was administered to 10 children (33.3%) aged 10 years or younger, and to 3 children (10%) over the age of 10 who exhibited uncooperative behaviour. Sedation was used for 17 children (56.6%). These findings slightly diverge from the study by Jee et al. [<xref ref-type="bibr" rid="CR18">18</xref>], where GA was employed for patients aged 7 years or younger, while those over 7 years were managed with sedo-analgesia [<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, their study reported that nearly third of the patients older than 7 years required conversion to general anaesthesia due to poor cooperation. In contrast, Shahat et al. used GA for all patients, explaining this decision by the younger ages of their study cohort (4.04&#x02009;&#x000b1;&#x02009;2.5) years [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par44">In terms of shock wave parameters, the number of shocks ranged from 1500 to 2500, with a force between 12&#x000a0;V and 16&#x000a0;V, and a frequency of 60 to 85 shocks per minute. These parameters are consistent with those reported by Shahat et al., Jee et al., and Jo&#x000e3;o Paulo da Cunha Lima et al. The variations observed in shock wave count, rate, and force can be attributed to factors such as patient cooperation, stone size, and stone density [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par45">Before the first SWL session, the patients were randomly assigned to either the Silodosin group or the placebo group. Our results showed a marginally higher one-session SFR in the Silodosin group (86.7%) compared to the placebo group (73.3%). However, this difference did not reach statistical significance (<italic>P</italic>&#x02009;=&#x02009;0.6), and the effect size was minimal, as indicated by a Cram&#x000e9;r&#x02019;s V of 0. 083.This finding suggests that while Silodosin may assist in the expulsion of stone fragments, it does not significantly impact the overall clearance of stones. One potential explanation for this could be the variability in stone fragmentation following SWL, which may influence the expulsion process.</p><p id="Par46">This result is consistent with the study by Elgalaly et al., which also reported no significant difference in treatment efficacy between silodosin and placebo for managing distal ureteric stones in paediatric patients [<xref ref-type="bibr" rid="CR10">10</xref>]. Similarly, Aydogdu et al. reported comparable findings in their study on doxazosin for distal ureteric stones [<xref ref-type="bibr" rid="CR3">3</xref>]. Conversely, Fahmy et al. found a significant difference in stone clearance between Silodosin (78.5%) and placebo groups (53.3%), as well as between Tamsulosin (66.6%) and placebo [<xref ref-type="bibr" rid="CR12">12</xref>]. Additionally, Mokhless et al. reported a significant enhancement in SFR among children receiving tamsulosin compared to those given placebo. Similarly, Erturhan et al. demonstrated that doxazosin was more effective than ibuprofen in promoting stone expulsion in paediatric patients with distal ureteric stones [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par47">The mean stone expulsion time was noticeably shorter in the Silodosin group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). This result agrees with findings by Elgalaly et al. and Fahmy et al., both of whom demonstrated that Silodosin significantly shortened the expulsion time for distal ureteric stones in children [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Additionally, Onur Telli et al. observed that doxazosin, as an adjunctive therapy after SWL for renal stones in children, reduced expulsion time more effectively than a watchful waiting approach [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par48">Pain scores and the requirement for analgesia during stone expulsion were also evaluated. The Silodosin group reported significantly lower pain scores compared to the placebo group (<italic>P</italic>&#x02009;=&#x02009;0.003). Similarly, the requirement for analgesics was notably greater in the placebo group compared to those receiving silodosin (<italic>P</italic>&#x02009;=&#x02009;0.008). These results are in agreement with previous findings by Elgalaly et al. and Fahmy et al., who similarly reported lower pain levels and decreased analgesic consumption among paediatric patients treated with silodosin during fragment stones passage [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par49">The safety profile of selective alpha-blockers in paediatric patients has been reported in several studies [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Doxazosin has been used without significant complications in various studies, and the FDA approved Tamsulosin for use in children in 2012 [<xref ref-type="bibr" rid="CR13">13</xref>]. In the current study, Silodosin was generally well tolerated, with side effects observed in only five patients, manifesting as mild gastrointestinal upset in 3 patients, including nausea and vomiting, while 2 patients complained from some episodic headache and dizziness. No patients discontinued treatment due to side effects. These results are consistent with the findings of Elgalaly et al. and Fahmy et al., who also demonstrated that Silodosin has a favourable safety and tolerability profile in children [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par50">Overall, this study demonstrated that Silodosin, when used as a MET following SWL in paediatric patients with renal stones, significantly reduced stone expulsion time and postoperative pain compared to placebo without significant adverse events.</p><sec id="Sec17"><title>Limitations of the study</title><p id="Par51">First, the sample size of only 30 patients, while sufficient for detecting large variability effects, indeed limits the ability to generalize the results. Second, we only included index patients with favourably positioned stones in the renal pelvis. Therefore, the results can&#x02019;t be generalized to cover all SWL scenarios where other factors can affect the success rate. Additionally, expanding the inclusion criteria to include patients with different types of stones (e.g., non-radiopaque stones) and comorbid conditions could provide a more comprehensive understanding of Silodosin&#x02019;s role in renal stone management across diverse clinical scenarios.</p><p id="Par52">Future studies with larger, multi-centre cohorts are essential to confirm the efficacy and safety of Silodosin in a broader paediatric population focusing on its use in different types of renal stones or with variations in SWL protocols to better understand its impact on stone clearance. Additionally, comparative trials with other alpha-blockers, such as Tamsulosin, would help elucidate whether Silodosin offers superior efficacy in paediatric patients.</p></sec></sec><sec id="Sec18"><title>Conclusion</title><p id="Par53">This study demonstrates that Silodosin could be a safe and effective adjunct therapy following SWL in paediatric patients with renal stones. It significantly reduces stone expulsion time, alleviates postoperative pain, and decreases the need for analgesics compared to placebo. While the results are promising, the study&#x02019;s small sample size and the lack of significant findings in stone clearance highlight the need for further research. Larger, multi-centre trials are warranted to confirm these findings and influence clinical guidelines.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>MLA and TG conceptualized and designed the study. MEE, OME, and MG were responsible for data collection and analysis. MLA, TG, and MEE contributed to drafting the manuscript. All authors were actively involved in conducting the study and critically reviewed the manuscript for significant intellectual input. Each author approved the final version for publication and accepted responsibility for the content. All authors ensured that issues concerning the accuracy or integrity of any part of the work were thoroughly investigated and appropriately addressed.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p><p>This research received no external funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par54">The study received ethical clearance from the Ethics Committee of the Faculty of Medicine, Tanta University (IRB approval number: 32649/10/18). It was conducted in line with the Declaration of Helsinki and adhered to CONSORT guidelines. Informed written consent was obtained from the guardians of all participating children. The study is retrospectively registered in the Pan African Clinical Trials Registry under the ID PACTR202503893791588.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdullah</surname><given-names>A</given-names></name><name><surname>Basoo Gupta</surname><given-names>Y</given-names></name><name><surname>Selvaraj</surname><given-names>S</given-names></name><name><surname>Ganapathy</surname><given-names>R</given-names></name><name><surname>Ilangovan</surname><given-names>AK</given-names></name><name><surname>Sivalingam</surname><given-names>S</given-names></name><etal/></person-group><article-title>A comparison between silodosin and Tamsulosin for medical expulsive therapy of distal ureteric Calculus</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e47008</fpage><pub-id pub-id-type="doi">10.7759/cureus.47008</pub-id><pub-id pub-id-type="pmid">37841986</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Abdullah A, Basoo Gupta Y, Selvaraj S, Ganapathy R, Ilangovan AK, Sivalingam S et al (2023) A comparison between silodosin and Tamsulosin for medical expulsive therapy of distal ureteric Calculus. Cureus 15:e47008. 10.7759/cureus.47008<pub-id pub-id-type="pmid">37841986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Aldaqadossi</surname><given-names>HA</given-names></name><name><surname>Shaker</surname><given-names>H</given-names></name><name><surname>Saifelnasr</surname><given-names>M</given-names></name><name><surname>Gaber</surname><given-names>M</given-names></name></person-group><article-title>Efficacy and safety of Tamsulosin as a medical expulsive therapy for stones in children</article-title><source>Arab J Urol</source><year>2015</year><volume>13</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.aju.2015.02.007</pub-id><pub-id pub-id-type="pmid">26413330</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Aldaqadossi HA, Shaker H, Saifelnasr M, Gaber M (2015) Efficacy and safety of Tamsulosin as a medical expulsive therapy for stones in children. Arab J Urol 13:107&#x02013;111. 10.1016/j.aju.2015.02.007<pub-id pub-id-type="pmid">26413330</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Aydogdu</surname><given-names>O</given-names></name><name><surname>Burgu</surname><given-names>B</given-names></name><name><surname>Gucuk</surname><given-names>A</given-names></name><name><surname>Suer</surname><given-names>E</given-names></name><name><surname>Soygur</surname><given-names>T</given-names></name></person-group><article-title>Effectiveness of Doxazosin in treatment of distal ureteral stones in children</article-title><source>J Urol</source><year>2009</year><volume>182</volume><fpage>2880</fpage><lpage>2884</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2009.08.061</pub-id><pub-id pub-id-type="pmid">19846149</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Aydogdu O, Burgu B, Gucuk A, Suer E, Soygur T (2009) Effectiveness of Doxazosin in treatment of distal ureteral stones in children. J Urol 182:2880&#x02013;2884. 10.1016/j.juro.2009.08.061<pub-id pub-id-type="pmid">19846149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Candau</surname><given-names>C</given-names></name><name><surname>Saussine</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>H</given-names></name><name><surname>Roy</surname><given-names>C</given-names></name><name><surname>Faure</surname><given-names>F</given-names></name><name><surname>Jacqmin</surname><given-names>D</given-names></name></person-group><article-title>Natural history of residual renal stone fragments after ESWL</article-title><source>Eur Urol</source><year>2000</year><volume>37</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1159/000020093</pub-id><pub-id pub-id-type="pmid">10671779</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Candau C, Saussine C, Lang H, Roy C, Faure F, Jacqmin D (2000) Natural history of residual renal stone fragments after ESWL. Eur Urol 37:18&#x02013;22. 10.1159/000020093<pub-id pub-id-type="pmid">10671779</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Chaussy</surname><given-names>C</given-names></name><name><surname>Brendel</surname><given-names>W</given-names></name><name><surname>Schmiedt</surname><given-names>E</given-names></name></person-group><article-title>Extracorporeally induced destruction of kidney stones by shock waves</article-title><source>Lancet</source><year>1980</year><volume>2</volume><fpage>1265</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(80)92335-1</pub-id><pub-id pub-id-type="pmid">6108446</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Chaussy C, Brendel W, Schmiedt E (1980) Extracorporeally induced destruction of kidney stones by shock waves. Lancet 2:1265&#x02013;1268. 10.1016/s0140-6736(80)92335-1<pub-id pub-id-type="pmid">6108446</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Coward</surname><given-names>RJ</given-names></name><name><surname>Peters</surname><given-names>CJ</given-names></name><name><surname>Duffy</surname><given-names>PG</given-names></name><name><surname>Corry</surname><given-names>D</given-names></name><name><surname>Kellett</surname><given-names>MJ</given-names></name><name><surname>Choong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epidemiology of paediatric renal stone disease in the UK</article-title><source>Arch Dis Child</source><year>2003</year><volume>88</volume><fpage>962</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1136/adc.88.11.962</pub-id><pub-id pub-id-type="pmid">14612355</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Coward RJ, Peters CJ, Duffy PG, Corry D, Kellett MJ, Choong S et al (2003) Epidemiology of paediatric renal stone disease in the UK. Arch Dis Child 88:962&#x02013;965. 10.1136/adc.88.11.962<pub-id pub-id-type="pmid">14612355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Zong</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis</article-title><source>Int Urol Nephrol</source><year>2012</year><volume>44</volume><fpage>1601</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1007/s11255-012-0261-6</pub-id><pub-id pub-id-type="pmid">22914879</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Cui Y, Zong H, Zhang Y (2012) The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis. Int Urol Nephrol 44:1601&#x02013;1609. 10.1007/s11255-012-0261-6<pub-id pub-id-type="pmid">22914879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>da Cunha Lima</surname><given-names>JP</given-names></name><name><surname>Duarte</surname><given-names>RJ</given-names></name><name><surname>Cristofani</surname><given-names>LM</given-names></name><name><surname>Srougi</surname><given-names>M</given-names></name></person-group><article-title>Extracorporeal shock wave lithotripsy in children: results and short-term complications</article-title><source>Int J Urol</source><year>2007</year><volume>14</volume><fpage>684</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2042.2007.01807.x</pub-id><pub-id pub-id-type="pmid">17681055</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">da Cunha Lima JP, Duarte RJ, Cristofani LM, Srougi M (2007) Extracorporeal shock wave lithotripsy in children: results and short-term complications. Int J Urol 14:684&#x02013;688. 10.1111/j.1442-2042.2007.01807.x<pub-id pub-id-type="pmid">17681055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Elderwy</surname><given-names>AA</given-names></name><name><surname>Kurkar</surname><given-names>A</given-names></name><name><surname>Hussein</surname><given-names>A</given-names></name><name><surname>Abozeid</surname><given-names>H</given-names></name><name><surname>Hammodda</surname><given-names>HM</given-names></name><name><surname>Ibraheim</surname><given-names>AF</given-names></name></person-group><article-title>Dissolution therapy versus shock wave lithotripsy for radiolucent renal stones in children: a prospective study</article-title><source>J Urol</source><year>2014</year><volume>191</volume><fpage>1491</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2013.10.060</pub-id><pub-id pub-id-type="pmid">24679880</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Elderwy AA, Kurkar A, Hussein A, Abozeid H, Hammodda HM, Ibraheim AF (2014) Dissolution therapy versus shock wave lithotripsy for radiolucent renal stones in children: a prospective study. J Urol 191:1491&#x02013;1495. 10.1016/j.juro.2013.10.060<pub-id pub-id-type="pmid">24679880</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Elgalaly</surname><given-names>H</given-names></name><name><surname>Eliwa</surname><given-names>A</given-names></name><name><surname>Seleem</surname><given-names>M</given-names></name><name><surname>Salem</surname><given-names>E</given-names></name><name><surname>Omran</surname><given-names>M</given-names></name><name><surname>Shello</surname><given-names>H</given-names></name><etal/></person-group><article-title>Silodosin in the treatment of distal ureteric stones in children: A prospective, randomised, placebo-controlled study</article-title><source>Arab J Urol</source><year>2017</year><volume>15</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.aju.2017.05.005</pub-id><pub-id pub-id-type="pmid">29071151</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Elgalaly H, Eliwa A, Seleem M, Salem E, Omran M, Shello H et al (2017) Silodosin in the treatment of distal ureteric stones in children: A prospective, randomised, placebo-controlled study. Arab J Urol 15:194&#x02013;198. 10.1016/j.aju.2017.05.005<pub-id pub-id-type="pmid">29071151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Erturhan</surname><given-names>S</given-names></name><name><surname>Bayrak</surname><given-names>O</given-names></name><name><surname>Sarica</surname><given-names>K</given-names></name><name><surname>Seckiner</surname><given-names>I</given-names></name><name><surname>Baturu</surname><given-names>M</given-names></name><name><surname>Sen</surname><given-names>H</given-names></name></person-group><article-title>Efficacy of medical expulsive treatment with Doxazosin in pediatric patients</article-title><source>Urology</source><year>2013</year><volume>81</volume><fpage>640</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2012.11.031</pub-id><pub-id pub-id-type="pmid">23343614</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Erturhan S, Bayrak O, Sarica K, Seckiner I, Baturu M, Sen H (2013) Efficacy of medical expulsive treatment with Doxazosin in pediatric patients. Urology 81:640&#x02013;643. 10.1016/j.urology.2012.11.031<pub-id pub-id-type="pmid">23343614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Fahmy</surname><given-names>A</given-names></name><name><surname>Rhasad</surname><given-names>H</given-names></name><name><surname>Kamal</surname><given-names>A</given-names></name><name><surname>Elsawy</surname><given-names>M</given-names></name></person-group><article-title>Mp90-18 silodosin for medical expulsive therapy in children with distal ureteral stone: A prospective randomized, Placebo-Controlled, single blind study study</article-title><source>J Urol</source><year>2017</year><volume>197</volume><fpage>e1217</fpage><lpage>e1217</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2017.02.2837</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Fahmy A, Rhasad H, Kamal A, Elsawy M (2017) Mp90-18 silodosin for medical expulsive therapy in children with distal ureteral stone: A prospective randomized, Placebo-Controlled, single blind study study. J Urol 197:e1217&#x02013;e1217</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Food AD (2012) Pediatric focused safety review: Flomax<sup>&#x000ae;</sup>(tamsulosin hydrochloride). Center for Drug Evaluation and Research</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Hollingsworth</surname><given-names>JM</given-names></name><name><surname>Rogers</surname><given-names>MA</given-names></name><name><surname>Kaufman</surname><given-names>SR</given-names></name><name><surname>Bradford</surname><given-names>TJ</given-names></name><name><surname>Saint</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Medical therapy to facilitate urinary stone passage: a meta-analysis</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1171</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69474-9</pub-id><pub-id pub-id-type="pmid">17011944</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT et al (2006) Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 368:1171&#x02013;1179. 10.1016/S0140-6736(06)69474-9<pub-id pub-id-type="pmid">17011944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>AI</given-names></name><name><surname>Shetty</surname><given-names>SD</given-names></name><name><surname>Awad</surname><given-names>RM</given-names></name><name><surname>Patel</surname><given-names>KP</given-names></name></person-group><article-title>Prognostic factors in the Conservative treatment of ureteric stones</article-title><source>Br J Urol</source><year>1991</year><volume>67</volume><fpage>358</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410x.1991.tb15161.x</pub-id><pub-id pub-id-type="pmid">2032074</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ibrahim AI, Shetty SD, Awad RM, Patel KP (1991) Prognostic factors in the Conservative treatment of ureteric stones. Br J Urol 67:358&#x02013;361. 10.1111/j.1464-410x.1991.tb15161.x<pub-id pub-id-type="pmid">2032074</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Kojima</surname><given-names>Y</given-names></name><name><surname>Yasui</surname><given-names>T</given-names></name><name><surname>Tozawa</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Kohri</surname><given-names>K</given-names></name></person-group><article-title>Examination of alpha 1 adrenoceptor subtypes in the human ureter</article-title><source>Int J Urol</source><year>2007</year><volume>14</volume><fpage>749</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2042.2007.01812.x</pub-id><pub-id pub-id-type="pmid">17681068</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K (2007) Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol 14:749&#x02013;753. 10.1111/j.1442-2042.2007.01812.x<pub-id pub-id-type="pmid">17681068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>A</given-names></name><name><surname>Yasui</surname><given-names>T</given-names></name><name><surname>Hamamoto</surname><given-names>S</given-names></name><name><surname>Hirose</surname><given-names>M</given-names></name><name><surname>Kojima</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy of selective alpha1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones</article-title><source>Int J Urol</source><year>2011</year><volume>18</volume><fpage>672</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2042.2011.02810.x</pub-id><pub-id pub-id-type="pmid">21707766</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Itoh Y, Okada A, Yasui T, Hamamoto S, Hirose M, Kojima Y et al (2011) Efficacy of selective alpha1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol 18:672&#x02013;674. 10.1111/j.1442-2042.2011.02810.x<pub-id pub-id-type="pmid">21707766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Jee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>SD</given-names></name><name><surname>Cho</surname><given-names>WY</given-names></name></person-group><article-title>Efficacy of extracorporeal shock wave lithotripsy in pediatric and adolescent urolithiasis</article-title><source>Korean J Urol</source><year>2013</year><volume>54</volume><fpage>865</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.4111/kju.2013.54.12.865</pub-id><pub-id pub-id-type="pmid">24363869</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Jee JY, Kim SD, Cho WY (2013) Efficacy of extracorporeal shock wave lithotripsy in pediatric and adolescent urolithiasis. Korean J Urol 54:865&#x02013;869. 10.4111/kju.2013.54.12.865<pub-id pub-id-type="pmid">24363869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Mokhless</surname><given-names>I</given-names></name><name><surname>Zahran</surname><given-names>AR</given-names></name><name><surname>Youssif</surname><given-names>M</given-names></name><name><surname>Fahmy</surname><given-names>A</given-names></name></person-group><article-title>Tamsulosin for the management of distal ureteral stones in children: a prospective randomized study</article-title><source>J Pediatr Urol</source><year>2012</year><volume>8</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.jpurol.2011.09.008</pub-id><pub-id pub-id-type="pmid">22099477</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Mokhless I, Zahran AR, Youssif M, Fahmy A (2012) Tamsulosin for the management of distal ureteral stones in children: a prospective randomized study. J Pediatr Urol 8:544&#x02013;548. 10.1016/j.jpurol.2011.09.008<pub-id pub-id-type="pmid">22099477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>DM</given-names></name><name><surname>Coury</surname><given-names>T</given-names></name><name><surname>Lingeman</surname><given-names>JE</given-names></name><name><surname>Mertz</surname><given-names>JH</given-names></name><name><surname>Mosbaugh</surname><given-names>PG</given-names></name><name><surname>Steele</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Extracorporeal shock wave lithotripsy experience in children</article-title><source>J Urol</source><year>1986</year><volume>136</volume><fpage>238</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/s0022-5347(17)44826-9</pub-id><pub-id pub-id-type="pmid">3723671</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Newman DM, Coury T, Lingeman JE, Mertz JH, Mosbaugh PG, Steele RE et al (1986) Extracorporeal shock wave lithotripsy experience in children. J Urol 136:238&#x02013;240. 10.1016/s0022-5347(17)44826-9<pub-id pub-id-type="pmid">3723671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Onen</surname><given-names>A</given-names></name></person-group><article-title>Grading of hydronephrosis: an ongoing challenge</article-title><source>Front Pediatr</source><year>2020</year><volume>8</volume><fpage>458</fpage><pub-id pub-id-type="doi">10.3389/fped.2020.00458</pub-id><pub-id pub-id-type="pmid">32984198</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Onen A (2020) Grading of hydronephrosis: an ongoing challenge. Front Pediatr 8:458. 10.3389/fped.2020.00458<pub-id pub-id-type="pmid">32984198</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>MM</given-names></name><name><surname>Alfano</surname><given-names>Y</given-names></name><name><surname>Kamp</surname><given-names>S</given-names></name><name><surname>Haecker</surname><given-names>A</given-names></name><name><surname>Alken</surname><given-names>P</given-names></name><name><surname>Michel</surname><given-names>MS</given-names></name><etal/></person-group><article-title>5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy</article-title><source>Eur Urol</source><year>2005</year><volume>47</volume><fpage>860</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2005.01.005</pub-id><pub-id pub-id-type="pmid">15925084</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Osman MM, Alfano Y, Kamp S, Haecker A, Alken P, Michel MS et al (2005) 5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy. Eur Urol 47:860&#x02013;864. 10.1016/j.eururo.2005.01.005<pub-id pub-id-type="pmid">15925084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zsoy</surname><given-names>M</given-names></name><name><surname>Liatsikos</surname><given-names>E</given-names></name><name><surname>Scheffbuch</surname><given-names>N</given-names></name><name><surname>Kallidonis</surname><given-names>P</given-names></name></person-group><article-title>Comparison of silodosin to Tamsulosin for medical expulsive treatment of ureteral stones: a systematic review and meta-analysis</article-title><source>Urolithiasis</source><year>2016</year><volume>44</volume><fpage>491</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1007/s00240-016-0872-y</pub-id><pub-id pub-id-type="pmid">27021350</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">&#x000d6;zsoy M, Liatsikos E, Scheffbuch N, Kallidonis P (2016) Comparison of silodosin to Tamsulosin for medical expulsive treatment of ureteral stones: a systematic review and meta-analysis. Urolithiasis 44:491&#x02013;497. 10.1007/s00240-016-0872-y<pub-id pub-id-type="pmid">27021350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>JK</given-names></name><name><surname>Hergan</surname><given-names>LA</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Lakin</surname><given-names>C</given-names></name></person-group><article-title>Efficacy of alpha-blockers for the treatment of ureteral stones</article-title><source>J Urol</source><year>2007</year><volume>177</volume><fpage>983</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2006.10.023</pub-id><pub-id pub-id-type="pmid">17296392</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Parsons JK, Hergan LA, Sakamoto K, Lakin C (2007) Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol 177:983&#x02013;987 discussion 987. 10.1016/j.juro.2006.10.023<pub-id pub-id-type="pmid">17296392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Pearle</surname><given-names>MS</given-names></name><name><surname>Lingeman</surname><given-names>JE</given-names></name><name><surname>Leveillee</surname><given-names>R</given-names></name><name><surname>Kuo</surname><given-names>R</given-names></name><name><surname>Preminger</surname><given-names>GM</given-names></name><name><surname>Nadler</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1&#x000a0;cm or less</article-title><source>J Urol</source><year>2005</year><volume>173</volume><fpage>2005</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000158458.51706.56</pub-id><pub-id pub-id-type="pmid">15879805</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pearle MS, Lingeman JE, Leveillee R, Kuo R, Preminger GM, Nadler RB et al (2005) Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1&#x000a0;cm or less. J Urol 173:2005&#x02013;2009. 10.1097/01.ju.0000158458.51706.56<pub-id pub-id-type="pmid">15879805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Research Randomizer [Internet] (2025) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.randomizer.org/">https://www.randomizer.org/</ext-link>. Accessed 30 March</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Sas</surname><given-names>DJ</given-names></name><name><surname>Hulsey</surname><given-names>TC</given-names></name><name><surname>Shatat</surname><given-names>IF</given-names></name><name><surname>Orak</surname><given-names>JK</given-names></name></person-group><article-title>Increasing incidence of kidney stones in children evaluated in the emergency department</article-title><source>J Pediatr</source><year>2010</year><volume>157</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2010.02.004</pub-id><pub-id pub-id-type="pmid">20362300</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sas DJ, Hulsey TC, Shatat IF, Orak JK (2010) Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr 157:132&#x02013;137. 10.1016/j.jpeds.2010.02.004<pub-id pub-id-type="pmid">20362300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Shahat</surname><given-names>A</given-names></name><name><surname>Elderwy</surname><given-names>A</given-names></name><name><surname>Safwat</surname><given-names>AS</given-names></name><name><surname>Abdelkawi</surname><given-names>IF</given-names></name><name><surname>Reda</surname><given-names>A</given-names></name><name><surname>Abdelsalam</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Is Tamsulosin effective after shock wave lithotripsy for pediatric renal stones?? A randomized, controlled study</article-title><source>J Urol</source><year>2016</year><volume>195</volume><fpage>1284</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2015.11.021</pub-id><pub-id pub-id-type="pmid">26926538</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Shahat A, Elderwy A, Safwat AS, Abdelkawi IF, Reda A, Abdelsalam Y et al (2016) Is Tamsulosin effective after shock wave lithotripsy for pediatric renal stones?? A randomized, controlled study. J Urol 195:1284&#x02013;1288. 10.1016/j.juro.2015.11.021<pub-id pub-id-type="pmid">26926538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Alter</surname><given-names>HJ</given-names></name><name><surname>Littlepage</surname><given-names>A</given-names></name></person-group><article-title>A systematic review of medical therapy to facilitate passage of ureteral calculi</article-title><source>Ann Emerg Med</source><year>2007</year><volume>50</volume><fpage>552</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2007.05.015</pub-id><pub-id pub-id-type="pmid">17681643</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Singh A, Alter HJ, Littlepage A (2007) A systematic review of medical therapy to facilitate passage of ureteral calculi. Ann Emerg Med 50:552&#x02013;563. 10.1016/j.annemergmed.2007.05.015<pub-id pub-id-type="pmid">17681643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Tailly</surname><given-names>GG</given-names></name></person-group><article-title>Extracorporeal shock wave lithotripsy today</article-title><source>Indian J Urol</source><year>2013</year><volume>29</volume><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.4103/0970-1591.117283</pub-id><pub-id pub-id-type="pmid">24082441</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Tailly GG (2013) Extracorporeal shock wave lithotripsy today. Indian J Urol 29:200&#x02013;207. 10.4103/0970-1591.117283<pub-id pub-id-type="pmid">24082441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Tasian</surname><given-names>GE</given-names></name><name><surname>Copelovitch</surname><given-names>L</given-names></name></person-group><article-title>Evaluation and medical management of kidney stones in children</article-title><source>J Urol</source><year>2014</year><volume>192</volume><fpage>1329</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2014.04.108</pub-id><pub-id pub-id-type="pmid">24960469</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tasian GE, Copelovitch L (2014) Evaluation and medical management of kidney stones in children. J Urol 192:1329&#x02013;1336. 10.1016/j.juro.2014.04.108<pub-id pub-id-type="pmid">24960469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tasian</surname><given-names>GE</given-names></name><name><surname>Cost</surname><given-names>NG</given-names></name><name><surname>Granberg</surname><given-names>CF</given-names></name><name><surname>Pulido</surname><given-names>JE</given-names></name><name><surname>Rivera</surname><given-names>M</given-names></name><name><surname>Schwen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Tamsulosin and spontaneous passage of ureteral stones in children: a multi-institutional cohort study</article-title><source>J Urol</source><year>2014</year><volume>192</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2014.01.091</pub-id><pub-id pub-id-type="pmid">24518765</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tasian GE, Cost NG, Granberg CF, Pulido JE, Rivera M, Schwen Z et al (2014) Tamsulosin and spontaneous passage of ureteral stones in children: a multi-institutional cohort study. J Urol 192:506&#x02013;511. 10.1016/j.juro.2014.01.091<pub-id pub-id-type="pmid">24518765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Tasian</surname><given-names>GE</given-names></name><name><surname>Kabarriti</surname><given-names>AE</given-names></name><name><surname>Kalmus</surname><given-names>A</given-names></name><name><surname>Furth</surname><given-names>SL</given-names></name></person-group><article-title>Kidney stone recurrence among children and adolescents</article-title><source>J Urol</source><year>2017</year><volume>197</volume><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2016.07.090</pub-id><pub-id pub-id-type="pmid">27521691</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Tasian GE, Kabarriti AE, Kalmus A, Furth SL (2017) Kidney stone recurrence among children and adolescents. J Urol 197:246&#x02013;252. 10.1016/j.juro.2016.07.090<pub-id pub-id-type="pmid">27521691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Telli</surname><given-names>O</given-names></name><name><surname>Gokce</surname><given-names>MI</given-names></name><name><surname>Ozturk</surname><given-names>E</given-names></name><name><surname>Suer</surname><given-names>E</given-names></name><name><surname>Mermerkaya</surname><given-names>M</given-names></name><name><surname>Afandiyev</surname><given-names>F</given-names></name><etal/></person-group><article-title>What is the best option for 10-20&#x000a0;mm renal pelvic stones undergoing ESWL in the pediatric population: stenting, alpha blockers or Conservative follow-up?</article-title><source>J Pediatr Surg</source><year>2015</year><volume>50</volume><fpage>1532</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1016/j.jpedsurg.2014.11.045</pub-id><pub-id pub-id-type="pmid">25783320</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Telli O, Gokce MI, Ozturk E, Suer E, Mermerkaya M, Afandiyev F et al (2015) What is the best option for 10-20&#x000a0;mm renal pelvic stones undergoing ESWL in the pediatric population: stenting, alpha blockers or Conservative follow-up? J Pediatr Surg 50:1532&#x02013;1534. 10.1016/j.jpedsurg.2014.11.045<pub-id pub-id-type="pmid">25783320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsze</surname><given-names>DS</given-names></name><name><surname>von Baeyer</surname><given-names>CL</given-names></name><name><surname>Pahalyants</surname><given-names>V</given-names></name><name><surname>Dayan</surname><given-names>PS</given-names></name></person-group><article-title>Validity and reliability of the verbal numerical rating scale for children aged 4 to 17 years with acute pain</article-title><source>Ann Emerg Med</source><year>2018</year><volume>71</volume><fpage>691</fpage><lpage>702e693</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2017.09.009</pub-id><pub-id pub-id-type="pmid">29107409</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tsze DS, von Baeyer CL, Pahalyants V, Dayan PS (2018) Validity and reliability of the verbal numerical rating scale for children aged 4 to 17 years with acute pain. Ann Emerg Med 71:691&#x02013;702e693. 10.1016/j.annemergmed.2017.09.009<pub-id pub-id-type="pmid">29107409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Kudoh</surname><given-names>J</given-names></name><name><surname>Homma</surname><given-names>Y</given-names></name><name><surname>Kawabe</surname><given-names>K</given-names></name></person-group><article-title>Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia</article-title><source>Clin Interv Aging</source><year>2011</year><volume>6</volume><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.2147/cia.S13803</pub-id><pub-id pub-id-type="pmid">21753871</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yoshida M, Kudoh J, Homma Y, Kawabe K (2011) Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging 6:161&#x02013;172. 10.2147/cia.S13803<pub-id pub-id-type="pmid">21753871</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>